Lonnie Pyne @lonniepyne.bsky.social · 03/09/2025Hi everyone. Lonnie Pyne, nephrologist from McMaster University in Hamilton, Ontario, Canada joining for #NephJC tonight. COI - one of the authors 3142
Reposted by Lonnie PyneMichael Walsh @lastwalsh.bsky.social · 19/08/2025Following #ACHIEVE our meta-analysis of RCTs of MRAs for pts receiving dialysis in @thelancet.com. Thanks to @lonniepyne.bsky.social for leading. No signal for benefit among low-risk of bias RCTs and a good demo of why we continue to need large simple trials. www.sciencedirect.com/science/arti...sciencedirect.comSafety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trialsMineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but the… 0122
Reposted by Lonnie PyneMichael Walsh @lastwalsh.bsky.social · 15/08/2025Proud to have worked with colleagues and friends around the world on #ACHIEVE. We're disappointed spiro didn't prevent CV death/heart failure hospitalizations, but we've shown it's possible to do publicly funded large RCTs of repurposed meds in ESKD. More to do! www.sciencedirect.com/science/arti...sciencedirect.comSpironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trialPatients undergoing maintenance dialysis for kidney failure are at substantial risk of cardiovascular morbidity and mortality. We aimed to establish i… 0112